Nutrien Ltd. has reported its third-quarter results for 2026, showcasing robust financial performance driven by record potash sales and operational excellence. The company also announced strategic changes regarding its phosphate business, including the closure of its White Springs facility, which is expected to enhance shareholder value.
In the third quarter, Nutrien achieved net earnings of $0.29 billion, translating to $0.60 diluted net earnings per share. The adjusted EBITDA for the quarter was reported at $1.31 billion, with adjusted net earnings per share at $0.61. Over the first nine months of 2026, the company generated net earnings of $1.65 billion and adjusted EBITDA of $4.85 billion.
Background
Nutrien Ltd. is a prominent player in the agricultural chemicals industry, classified under SIC 2870. The company trades on the New York Stock Exchange under the ticker symbol NTR. Nutrien focuses on providing essential crop nutrients and services to farmers globally, aiming to enhance agricultural productivity.
What the Filing Says
The recent filing highlights that Nutrien's strong performance is attributed to structural earnings growth and increased cash returns to shareholders. President and CEO Ken Seitz stated, "Nutrien delivered structural earnings growth and increased cash returns to shareholders in the first nine months of 2026, supported by record potash sales volumes, strong proprietary products gross margins and a continued focus on operational excellence." Additionally, the company completed a strategic review of its phosphate business, deciding to retain and optimize its Aurora facility while shutting down the White Springs facility in the second quarter of 2027.
Impact
The changes announced by Nutrien may significantly affect its operational strategy and financial outlook. The closure of the White Springs facility, which is nearing the end of its economically recoverable reserve life, is expected to reduce annual sustaining capital expenditures and lease payments by approximately $50 million. This decision is anticipated to improve adjusted EBITDA and free cash flow in the long run.
What's Next
The filing does not specify what happens next regarding further strategic actions or additional filings. However, Nutrien's commitment to enhancing shareholder value and optimizing its operations suggests that the company will continue to focus on its core assets and operational efficiencies.
Read Next
Liberty Latin America reports Q3 2026 results amid challenges
Mineralys Therapeutics Reports Q3 2026 Financial Results
ADMA Biologics reports quarterly results, highlights growth
ProtoKinetix Reports Q1 2026 Results Amid Industry Challenges
National Healthcare Properties reports Q3 2026 results
Encore Capital Group Reports Q3 2026 Financial Results




